Review Article

FUTURE JOURNAL OF PHARMACEUTICALS AND HEALTH SCIENCES

Published by Pharma Springs Publication Journal Home Page: https://pharmasprings.com/fjphs

A Review on regulatory affairs and regulatory requirements for drug approval

Kishore Bandarapalle*[1], Rajasekhar Komarla Kumarachari [2], Kamasani Teja Sri[1], Boyalapalli Neeraja[1], Chejarla Likhitha[1], Krishna Chaitanya[1], C Y Bhargavi[1]

[1]Department of Pharmaceutics, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Chittoor, Andhra Pradesh 517503, India.

[2]Department of Pharmaceutical Chemistry, Sri Padmavathi School of Pharmacy, Tiruchanoor, Tirupati, Chittoor, Andhra Pradesh 517503, India

Article History:

Received on: 04 Dec 2023
Revised on: 05 Jan 2024
Accepted on: 07 Jan 2024

Keywords:

Regulatory affair,
Safety,
efficacy,
Clinical Investigation

Abstract

Regulatory affairs are a new profession that can be developed for the controlling the safety, quality and efficacy of the drug products by submitting the investigational new drug application (IND) and new drug application (NDA) to regulatory authority. The whole process may be done in conscious manner in order to release a safe drug product to protect the public from toxic effects of drugs during and after the usage of drugs. The main intention of this article was to aware the peoples towards the role of regulatory affairs department, requirements for new drug approval and the involvement of the regulatory professionals in this process as well as how crucial it is to perform and monitor the clinical and nonclinical trials of the drug before marketing the drug.

∗Corresponding Author
Name: Kishore Bandarapalle
Phone: +91 7995536331
Email: kishore.brr89@gmail.com

eISSN: 2583-116X
DOI: https://doi.org/10.26452/fjphs.v4i1.550

Production and hosted by
Pharmasprings.com

INTRODUCTION

Within regulated industries including pharmaceuticals, medical devices, and other items, there is a profession known as regulatory affairs (RA), also known as government affairs. Collecting, analyzing, and communicating the risks and benefits of healthcare goods to regulatory bodies and the general public around the world are the core competencies of the RA profession. A science that focuses on creating new instruments, benchmarks, and methods to evaluate the performance, efficacy, quality, and safety of regulated items. All medications must satisfy three requirements: they must be of high quality, safe, and effective. Decisions about the effectiveness, safety, and quality of medicines should be supported by sound scientific evidence Additionally, the term "regulatory affairs" has a particularly specific connotation in the healthcare sector (which includes the pharmaceutical, medical device, biologic, and functional food businesses). The understanding, application, and communication of regulatory strategy are critical to its success [1].

Table 1 List of legislations

Year	Legislations	Aim
1906	Pure Food and Drug Act	Prevent false claim
1919	Poisons Act	To control the cheap products& its flow in market. procession of poisonous substances.
1930	Dangerous Drug Act	It regulates cultivation, production, import, export and marketing of opium and its plant
1940	Drug& Cosmetic Act	It regulates production, import, export, marketing of drug products.
1948	ACT in Pharmacy	To govern the pharmacy profession
1955	Drugs & Magic Remedies Rules Act	To control advertising the pharmaceutical products.
1985	Narcotic & Psychotropic Drugs Act	To regulate the Narcotics & Psychotropic drugs.
1938	Federal Cosmetic, Drug, and Food Act	Before being marketed, safety must be demonstrated.
1987	Act on Prescription Drug Marketing	It guarantees that consumer-purchased pharmaceuticals are safe, effective, and free of subpar, expired, adulterated, counterfeit, or misbranded medications.

Regulatory affairs:

Regulatory affairs are a new profession that is developed from governments to protect public health. It ensures safety, efficacy, quality of a drug products and medical devices. The regulatory affairs department may involve in the events that are discussed below:

- Advise on product development.
- Verify IND application for giving permission for clinical and non-clinical trials.
- Give IND extension/updates.
- Give Approval from regulatory authority.
- It demands Marketing Authorization Application (MAA) or New Drug Application (NDA).
- MAA approval.
- Renewal.

Historical overview of regulatory affairs:

The regulatory affairs department can be established based on government desires. And for regulating the severe adverse consequences in public health. Actually, regulatory affairs can act as interphase between pharmaceutical industry and regulatory body. During 1950‘s there was many disasters were happened due to the invalid judgement of professionals. During the manufacturing and incidence of adulteration of drug substances which cause death of patients.

So due to this after this incident the government was thinks to establish the regulatory bodies which gives new regulations related on quality, safety, efficacy of new drug products [2].

Disasters out of India:

In 1935 oral elixir of sulphanilamide , in this elixir diethylene glycol is used as solvent but it acts as a poisonous solvent, when it administered to patients, it may leads to 100 + deaths of patients due to this the government introduced the Food and Drug Cosmetic Act implemented in 1938 AD. Between 1961-1962 the thalidomide tragedy occurs, when it can be given to pregnant women‘s for curing morning sickness(nausea, vomiting) but it may cause severe action that is leads to 200+ death of children‘s and 10,000 children‘s are leads to severe birth defects [3].

History of regulatory affairs in India:

Till 20th century the pharmaceutical products import from other countries, so after world war- 1 in 1914. Due to increased demand for the drug products, many substandard drug products enter

Table 2 List of regulatory authorities in different countries

COUNTRY	AUTHORITY
India	Central Drug Standard Control Organization (CDSCO)
United States of America (USA)	Food And Drug Administration (FDA)
Japan	Pharmaceutical and Medical Devices Agency (PMDA)
Australia	Therapeutic Goods Administration (TGA)
Canada	Health Canada
France	National Agency for the Safety of Medicine and Health Products (ANSM)
Germany	Federal Institute for Drugs and Medical Devices
Greece	National Organization for Medicines
China	National Medical Products Administration
Europe	European Medicine Agency
Pakistan	Drug Regulatory Authority of Pakistan
Malaysia	National Pharmaceutical Regulatory Agency (NPRA)
Saudi Arabia	The Saudi Food and Drug Authority (SFDA)
UAE	The UAE Ministry of Health (MOH)
Philippines	The Food and Drug Administration
Bangladesh	Directorate General of Drug Administration (DGDA)
Israel	Ministry of Health
Nepal	Department of Drug Administration
South Korea	The Ministry of Food and Drug Safety (MFDS)
Hungary	National Institute of Pharmacy and Nutrition

into market, to control these products, many legislations were made from time to time [4][5].

Regulatory authorities:

Regulatory authority is a regulatory body which conduct the regulatory activities relating to medicines, it includes processing and marketing authorizations, monitoring the adverse drug reactions & side effects, inspection, monitoring the safety of medicines and quality testing. It can be created by government to oversee and enforces the regulations regarding occupational health & safety of medicinal products [6].

List of international regulatory authorities:

1. WHO -World Health Organization
2. ICH - International Council for Harmonization
3. WIPO- World Intellectual Property Organization

Role of regulatory affairs:

- It is a unique combination of Science and Management.
- It is the first point of contact between pharmaceutical company and Regulatory Authority.
- It helps in knowing legislations implementing legislations and get approval for the legislations laid down by Regulatory Authorities.

Role of Regulatory Affairs in Production:

- Role of Regulatory Affairs started from product development to marketing, marketing to post marketing surveillance.
- Regulatory Affairs give advises at all stages with respect to technical requirements.
- Regulatory Affairs should ensure the labelling and packing of drug products.

Role of Regulatory Affairs in Clinical Studies:

It should collect, analyses and communicate the obtained data to Regulatory Authorities for approval.

Role of Regulatory Affairs in Research and Development:

It should work together with Research and Development and marketing to develop novel drug product by using latest technologies and Regulatory Development

Role of Regulatory Affairs in Quality Control and Quality Assurance [7]:

In collaboration with QC and QA the Regulatory Authorities should submit the Dossier (documentation containing all details) which includes

1. Certificate of Analysis
2. Stability studies
3. Analytical Method Validation Report
4. Process Validation Report
5. Master Formula Record to Regulatory Authorities for approval.

Role of Regulatory Affairs in licensing:

Regulatory Affairs should all the supporting documents to Regulatory Authorities for licensing/approval.

Functions of Regulatory Affairs Department [8]:

Regulatory Affairs is a new profession created by governments to protect public health by regulating the safety and efficacy of products in specific sectors. Regulatory Affairs departments are growing, changing, and becoming larger within businesses. They are also the ones that are least affected by mergers and acquisitions, as well as by recessions. Due to global standardisation, regulatory submissions and, consequently, reviews, are now handled consistently. This section is in charge of comprehending the regulatory requirements for obtaining new/generic products approved. They are aware of the pledges made by the corporation to the regulatory agencies where the product will be approved. They also provide the agencies with annual reports and supplements. This profession serves as a liaison between the pharmaceutical sector and drug regulatory authorities worldwide. This department is primarily responsible for registering drug items in their respective nations prior to marketing. It may be of the following types

1. Origin country under Domestic Regulatory Affairs (DRA)
2. Other than country of origin: International Regulatory Affairs (IRA).

Responsibility of Regulatory Affairs Professionals:

In current competitive world the role of Regulatory Affairs is to minimize the approval time for the drug product is beneficial commercially in pharmaceutical company.

Qualities of Regulatory Affairs Professionals:

1. Good Analytical Skills
2. Good Communication Skills
3. Good Presentation Skills
4. Good Computer Skills
5. Good Decision Skills
6. Project Management Skills

Regulatory affairs professionals will pay a great attention and their responsibilities may include as follows.

- Regulatory affairs professionals have 'Right first time' approach & they will play a key role in coordinating scientific Endeavor with regulatory specifications throughout the shelf life of product, helps to reduce the cost use of company resources.
- It leads to take long period of time for providing a new drug to the market. So, this process should be more relevantly from starting to end in order to meet regulatory specifications and demands.
- The above process can be done by the regulatory affairs professionals only in each phase of this process.
- The professionals of regulatory affairs department will register the documents
- The main responsibility of regulatory affairs professionals is to secure the approval of drug submissions from good therapeutic products program.
- They must have a prodigious scientific background & have a brilliant brainy on domestic regulations as well as international regulations.

- They must effectively participate in discussion to get an all the relevant documentation [9].

Requirements for new drug approval are stated below;

Drug development teams:

The scientific disciplines are the persons and are named as drug development teams who involved in the drug discovery and drug development process for as many as 10 to 12 years [10].

Nonclinical drug development:

Non clinical studies are important for drug development. They can be performed by using various GLP (Good Laboratory Practises) requirements should be adhered to by protocols, including animal research. In the initial phase of pre-clinical development, a prospective medication must undergo various assessments, including determining the drug's availability, absorption, distribution, metabolism, and elimination (ADME) and conducting preliminary studies to look into public safety issues like mutagenicity, genotoxicity and general toxicology.

Pharmacology:

Pharmacology and clinical trials are important to assure the safety and efficacy of the new drugs.

It is essential for making well-informed decisions when developing new drugs. It mainly focuses on the effects and actions of drug in humans. The main responsibility of this test is to find out the possible unwanted or toxic effects of exposure of drug in therapeutic doses. Pharmacology in drug development play a precious role to examine the effects of chemical substance on living organism. It involves all the concepts of drug identification, ranging from details drug interaction and its target to consequences of placing the drug in the market.

Safety pharmacology [11][12]:

- It involves analysing and researching the pharmacological effects of possible drugs that could endanger life. This is unrelated to the intended treatment outcome.
- They conduct the tests at amounts that don't significantly above the prescribed clinical dose.
- Safety pharmacology may aim to discover unanticipated actions of newly processes drugs on major organ function.
- It is complex process and time-consuming process. The main components in safety pharmacology are pharmacokinetics, pharmacodynamics and pharmacogenomics.
- It involves in selecting the optimal dose for phase -1, phase-2and phase-3 clinical trials and generate bioequivalence and bio similar studies.
- It is a powerful tool to optimize the drug safety in clinical trials for both patient care and medication development.

Phase-1 clinical trial is vital in turning experimental findings into clinical applications and in deciding whether to continue or discontinue development of promising novel medicines. Phase 1 trials, often known as first-in-human studies, are intended to investigate experimental new medications as well as new combinations or dose schedules of FDA-approved drugs.

A Phase 1 clinical trial's target population is often made up of healthy volunteers.

These individuals provide the best group to analyse clinical pharmacology since they don't interfere with or affect the evaluation of the drug's safety profile due to pathological conditions. Basic PK data on a novel medicine candidate is provided via clinical trials involving healthy volunteers. They boost the study's accrual rate and reduce ethical concerns about enrolling the participant to get a treatment.

Population pharmacokinetics and pharmacodynamics (PK/PD) analysis can be used to predict results in a wider population at this phase, even though Phase II studies only demonstrate drug efficacy and safety in a small number of patients. The estimated effect size, which is used to determine sample size and plan Phase III research, and the optimal dose for the subsequent trial are determined by the analysis. This is done by measuring the PK variability in the target group, identifying factors that potentially alter the. conducting exposure-response analyses and clinical trial simulations, as well as PK parameters. A wide range of presumptions and

conditions, including larger dosages than those investigated in Phase II studies, various sample sizes, and alternative study designs, can be used to imitate clinical trials.

To ascertain the efficacy and safety of the study drug on a bigger scale, phase III studies, sometimes referred to as pivotal trials, are carried out with a larger sample size.

Phase III allows for the confirmation of therapeutic efficacy in a variety of demographics as well as dose adjustment in certain populations. In this Phase, population PK/PD is still utilized to assess the efficacy of the chosen therapeutic dose, maybe establish a therapeutic window for the study drug, and predict drug exposure and response when several medicines are used. Unaccounted-for variances can be reduced by finding additional covariates. Based on unique traits like weight and genotype, this could offer patient-specific medication. If the studies are used as evidence, it will be the easier to register the drugs.

Metabolism [13]:

One of the most significant indicators of a new chemical entities pharmacokinetic disposition is its metabolism by the host system.

In most cases, a xenobiotic metabolic change precedes its elimination from the presenter. Therefore, the general disposition of the xenobiotic is likely to be impacted by any factor that affects the rate and extent of metabolism. In most cases, metabolism results in medication deactivation. However, the metabolic modification of a xenobiotic may result in the formation of an active metabolite.

The optimization of drug metabolism in preclinical research is a special challenge. There is variation in metabolism both across patients and between organs. Hydroxylation, reduction, and hydrolysis are only a few examples of chemical changes. Proteins that are differentially expressed in different organs—for example, liver hepatocytes that primarily express cytochrome P450 enzymes—and may have a wide variety of nucleotide polymorphisms mediate these processes. Additionally, for biotransformation to take place, the medication must come into contact with these proteins. Drug transport into and out of target cells are also taken into account while analyzing drug metabolism. Diffusion dynamics and specialized proteins, such as organic anion transporters (OATs) for drug uptake and P-glycoprotein for drug efflux, mediate transport. consequently, small-molecule drug metabolism is crucial to the drugs.

Toxicology [14]:

It is the most important regulatory requirement for new drug approval process.

The main principal involved in toxicity studies is Dose-response.

It aims to evaluate the level of toxicity of the substance by using protocols that must follow the guidelines provided to conduct the non-clinical studies of new drug product to identify any adverse or toxic events prior to new drug that being administer to volunteers who participating during clinical trials.

Regulatory requirements for toxicity studies are t the study the weight variation of animal used should be minimal & not exceeded+_20% of mean weight of each sex.

Toxicity studies are conduct for new drug molecule to make molecule essential for drug development process.

Toxicity study tests are generating the reactions and environmental exposure.

General considerations of investigational new drug

IND Application process:

- Novel medication or biological product suitable for clinical research purpose is called as investigational new drug (IND). The term also indicates new product that can be used for diagnostic purpose.
- When the new molecule can be developed after preclinical investigation that has been recorded/tested for possible acute toxicity and pharmacological action within animals.
- After that, FDA approval is needed for the clinical trials.
- The guarantor/financer submits the application for performing the clinical trials on humans is called as IND application.

- Once the submission of IND application is completed, he/she needs to wait thirty days before starting a clinical study.
- Following FDA and local institutional review board (IRB) assessment of the IND then only the clinical trials begin in humans.
- IRB approve clinical trial protocol, informed to all the participants & provide suitable steps to prevent the things from harm.
- Within 30 days of submission, if the FDA accepts the IND request, the investigator can start the clinical trials studies on new molecule performed on humans.
- At this time this new drug molecule requires drug regulatory system.
- During clinical studies, if at any time the data submitted to FDA indicates to be toxic under the risk ratio, FDA can prevent the clinical trials & its actions are not applicable to any judicial review.

The issues are related to as follows:

- ✓ Review the chemistry, production, and oversight of experimental drugs. .
- ✓ Protocol for the clinical trials performance.
- ✓ Design of animal research [15].
- IND application can be submitted to provide the information demonstrating that it makes sense to begin testing new drugs on humans.
- During pre -clinical drug development the sponsors or the guarantors primary aim is to determine the if the product is at least somewhat safe for people to use when they first start using it and produce the justified activity.
- When the drug can be discovered by various candidates for additional growth. The sponsor then concentrates on gathering information and data, which is required to demonstrate that the product won't put people at undue risk when utilised in small, straightforward clinical studies.

Classification of IND application:

These are two types;

Commercial IND application

The companies are submitted IND application to get marketing approval for new product.

Non-commercial IND application:

In this the IND application can be submitted for non-commercial research purpose. Allow the guarantor to use drug in research to get advanced knowledge of new drug, no plan to market the product.

Types of IND application:

Investigator IND application

Emergency IND application

Treatment IND application

Screening IND application

Investigator IND application:

It can be submitted by physician, whose responsibility is to conduct the investigation.

Physician must submit a research IND to response studying an unapproved drug.

Emergency IND application:

It can allow the FDA to authorizes the usage of an investigational medication in a critical situation.

Emergency IND does not give enough time to submit the IND in compliance with 21CFR, SEC312-23.

Treatment IND application:

It shows promises in clinical testing for adverse conditions while the clinical work is conducted.

It can be conducted for experimental drugs.

Screened IND application:

It can be filled for several, closely similar molecules to filter the desired ingredients.

The IND application must provide the information in 3 broad areas:

Animal pharmacology &toxicology:

It includes pre-clinical evidence to establish the product's suitability for human experimentation.

Manufacturing information:

It includes the information related to manufacturer stability& control used for

manufacturing the medicinal product to assess that the company can suitable to produce& supply the constant/ standard batches of medicines.

Clinical protocol & investigator information:

It includes information on the qualification of physicians, if they fulfill their clinical duties.

Finally, from all research reports the dedication obtained for review of the study by IRB &to strictly sticking to the IND regulations.

Withdrawal of an IND:

The sponsor has right to withdraw an IND at any condition without prejudice.

On with drawing the IND the sponsor must notify the FDA& IRB with reason for withdrawal.

Investigators Brochure:

The Investigator's Brochure (IB) is a diverse document that describes the key features of a development program's progress to date. Although the IB has extra objectives, it is primarily created to allow clinical investigators to assess the risks and benefits of an experimental drug. In accordance to the ICH E6 guideline, an IB should include information on the investigational product as well as its use in non-clinical and clinical research, as well as a section providing investigator guidelines on drug use.

Apart from the necessityMedical writers' primary responsibility and challenge when it comes to project management is to make sure that the information they provide in an IB is as balanced, focused, and concise as possible while still conveying all the information an investigator needs to know about using the investigational product. IB consist following contents, they are described below

- Summary
- Introduction
- Physical & chemical properties
- Pharmaceutical properties
- Formulation properties
- Non clinical studies

Summary:

The 'Summary' part of an IB is the first important section, and it should include a synopsis of the parts that follow, along with a profile of information on the physical, chemical, medicinal, toxicological, pharmacokinetic, and metabolic aspects of the subject matter of the drug substances and their clinical data.

As per ICH E6, the summary of IB should not more than two pages.

Introduction:

The introduction gives bright overview of investigational product.

It mainly contains the following elements and their information:

Generic name and Trade name of the drug product.

Its active ingredients

Pharmacological class

State of the product where it being investigated in the class

Potential activity with comparison to other product

It provides the investigational approach in which they are already conducted. One possible source of information is the clinical development plan. which can be prepared previously. The IB team members can give some sections of IB.

Physical and chemical, pharmaceutical properties and formulation:

This is a succinct section that outlines the chemical, physical, and pharmacological characteristics of the investigational product in terms of the drug product and, if relevant, the drug substance. The objective of this section is to provide the investigator with sufficient information about the investigational product to ascertain any potential risks associated with the drug or any excipients. It should also include handling and storage instructions, as well as any necessary steps prior to administration, like reconstitution or dilution. The information for this section is usually provided by the Sponsor's Chemistry, Manufacturing, and Controls (CMC) department, though the writer might have to format the information appropriately for the IB.

Non-clinical studies:

Non-clinical studies play an important role in the initial version of an IB since they provide the only evidence on which benefits and dangers may be judged prior to delivering the experimental drug in humans for the first time. Although details of exploratory investigations may be deleted if they have been overtaken by more extensive research delivering the same type of information, a complete summary of the informal profile is essential. ICH E6 should give the information for non-clinical studies, that are intensity and frequency of pharmacology and toxicological effects of drug substances.

New drug application (NDA):

Following the development of a pharmaceutical, animal pre-clinical trials are conducted to ensure its safety and efficacy. To gain permission to perform clinical research, an application must be submitted to the appropriate country's competent authority. Before adjusting the pharmaceutical dose in humans, clinical investigations are undertaken in four stages to assure safety and efficacy. The drug is then approved by the appropriate authorities once a Marketing Authorization Application (MAA) is filed, if it satisfies safety and efficacy requirements and shows that the advantages outweigh the dangers [30].

An NDA is a request to a regulatory authority for approval to commercialize a novel drug, often known as an innovative product. To acquire this approval, A description of manufacturing trials and the results of preclinical and clinical tests must be submitted by the sponsor in order to analyse drug information.

Preclinical research First phase: clinical study Phase II: Investigative experiment Phase IV is the post-marketing phase, whereas Phase III is the confirmatory trial.

After the agency receives the NDA, it goes through a technical screening. This examination confirms that sufficient facts and information have been presented in each area to support "filing" the application.

All research data from preclinical to Phase 3 clinical trials must be provided by the drug sponsor in order to submit a new drug application (NDA), as well as the following papers:

- Proposed labeling
- Safety updates
- Drug abuse information
- Patent information
- Location of clinical trial trials
- Compliance Preclinical research report
- Usage instructions

NDA Review - Once the NDA is received by the regulatory body, it is subjected to a technical screening. This examination confirms that sufficient facts and information have been supplied in each area to justify NDA submission.

At the conclusion of the NDA review, there are three different results that might be sent to the drug sponsor:

1. Unacceptable- it displays a list of faults and explains the reason for rejection.
2. Acceptable - minimal adjustments are suggested for marketing clearance.
3. Marketing authorization granted.

It will take 6 - 12 months following NDA submission to receive marketing approval letter.

Clinical research/bioequivalence studies [16]:

Studies on bioequivalence (BE) are carried out to determine whether different medication product formulations or regimens are comparable in terms of their nontherapeutic side effects (safety) and therapeutic benefit (efficacy). They play a significant and essential role in the drug development process by guaranteeing that safety and efficacy are maintained when a patient switches to a new formulation available on the market.

Regulatory, pharmacokinetic, and statistical subject matter experts must play a major role in bioequivalency studies and employ multidisciplinary techniques. For a bioequivalency study design to be successful, cooperation between research scientists and biostatisticians is crucial. Two items are typically administered in a bioequivalency research study: T (test product) and R (reference product).

Parallel and crossover designs are thus common bioequivalency study strategies. In a parallel trial, participants are randomised to either of two therapy groups (T or R), and both groups get parallel tracking. Because of this, for the course of the trial, every single patient in a parallel study is only given one of the two drugs (i.e., T or R). In a crossover trial, every participant is given both medications (T and R); one during one research segment and the other during a different one (i.e., consecutively). Patients are randomly assigned to one of two sequence groups in a crossover study. First, the test drug is administered to subjects in sequence group 1 (i.e., TR), and then the reference medication. The experimental drug is administered after the reference drug to subjects in sequence group 2 (i.e., RT).

Clinical trial protocol:

The goals, design, methods, statistical considerations, and organisation of a clinical trial are all outlined in the clinical trial protocol, which also guarantees the trial subjects' safety and the accuracy of the data gathered. clinical studies carried out according to the guidelines of the ICH and good clinical practise (GCP). E6 (R2) Integrative Clinical Practise: ICH Addendum The GCP-ICH rules are contained in E6 (R1). In general, a trial protocol should have the following items.

1) General information
2) Background information
3) Trial Objectives and Purpose
4) Trial Design
5) Selection and Withdrawal of Subjects
6) Treatment pf subjects
7) Assessment of Safety
8) Assessment of Efficacy
9) Statistics
10) Direct Access to Source Data/Documents
11) Quality Control and Quality Assurance
12) Ethics
13) Data Handling and Record Keeping
14) Financing and Insurance
15) Publication Policy
16) Supplements

Management of clinical studies [17]:

The following are the essential components of clinical program management**.**

Investigator selection:

The US GCP Rules and Regulations and the ICH GCP Guidelines mandate that the manufacturer take only investigators who are qualified as appropriate experts by training and experience to evaluate an experimental product (21 CFR 312.53). A comparable reference can also be found in the ICH GCP Guidelines.

Pre investigational site visits (PISV):

Following the pre-screening process, potential investigators must participate in a PISV at the investigational site with their personnel in order to further assess their suitability for the project. The PISV is often carried out by the monitor or another authorised person designated by the sponsor company.

Study initiation visits (SIV):

Following the finish of the PISV, a SIV is the next stage. The beginning visits functions as a training program. This is the final protocol training that the investigators and team members will get before commencing to recruit and enroll subjects in the trial. During this meeting, the monitor will go over the study protocol, adverse experience and major adverse experience reporting records, reports, and so on. Distribution of goods and duty, completion of the Case Report Form (CRF), Analyze regulatory documents and source documents.

Trial conduct and execution:

Participant selection, informed consent, IRB/IEC approval, product responsibility, reporting of unpleasant experiences and reactions, financial transparency, and documentation conservation are all critical components of trial execution. Each is essential to a clinical trial's overall success.

Periodic monitoring visits:

The sponsor is required by the CFR and the ICH GCP standards to keep an eye on the clinical trial's advancement at the trial site. These recurring visits by the sponsor's monitor are primarily intended to ensure that the investigators and their

personnel comply with GCP regulations and guidelines as well as the protocol in order to safeguard the rights of the subjects taking part in the clinical trial and ensure that the data reported is accurate, complete, and independently verified.

Subject Recruitment:

One of the most certain ways to reduce the overall time involved in a clinical trial is to recruit individuals as soon as feasible. Planning how and where to gain a subject population is the key to effective subject recruitment. In order to plan for recruitment, one must first identify and comprehend the subject group that meets the process's criteria. Why are these participants in the clinical experiment motivated to participate? With whom are they currently seeing to obtain healthcare, and what kind of treatment are they currently receiving? In what state is their health at the moment?

Product accountability:

Clinical studies examine novel experimental drugs/devices that have not yet acquired marketing authorization from the appropriate health care authority. As a result, any investigational product must be subjected to tight control. The investigator is accountable for the test product. Only the investigator or authorized sub investigators should prescribe investigational products. The sponsor is responsible for gathering and verifying the disposition of any used and unused merchandise. Product records in detail Throughout a trial, Accountability needs to be upheld by keeping records of the date, quantity, subject recognition (subject number), and batch number of the prescribed product that was dispensed [18].

Adverse Experiences and Adverse drug reporting:

Drug safety and complaints are inversely proportionate. In the United States, drug safety is strictly regulated by the FDA. Federal laws require a sponsor to record adverse experiences and responses for a testing product during both thediscover and post marketing times.

Financial disclosure:

Economic disclosure is one of the most recent modifications to a clinical trial. This regulation, which went into effect in the United States on February 2, 1999, pertains to any current or going on clinical trials that have been presented in an IND. The FDA defines financial disclosure as compensation related to the study's outcome, proprietary interest in the product (e.g., patent), significant equity interest in the study's sponsor, and significant payments of different kinds to the investigator or institution (e.g., equipment, honoraria). Ensuring the FDA that sufficient measures were taken to prevent bias in the design, conduct, reporting, and analysis of studies—even in cases where the investigator has a financial interest in a new product—is the goal of this regulation.

Study close-out visits (SCV) [19]:

When a trial at an experimental site concludes, the study must be correctly closed. This will not be possible until all subjects have finished the trial, or have been dropped or quit, and all concerns and questions about the data have been addressed in the final evaluations. Only once this has been completed may the monitor move to the close-out visit. The monitor will finish the SCV using the checklist below: The trial's volunteers have all been identified. All CRF pages have been finished and stored. All data questions have been resolved. All AEs and ADRs have been reported and investigations are underway. All testing products have been accounted for and either discarded or returned to the sponsor. All remaining supplies (CRFs, ancillary supplies) are properly returned or disposed of. The Trial Binder provides complete and arranged regulatory records. All outstanding issues have been solved.

Records retention and inspections:

Record preservation is important for the study data's long-term its reliability. After filing a new drug application (NDA), the FDA or other health authorities may conduct an on-site examination to confirm information from a specific location. The website ought to have easy access to this information. After a marketing application is submitted, records must be retained for two years, according to both the ICH and the CFR [20].

CONCLUSION:

Companies are rapidly expanding their regulatory affairs departments in order to meet the regulatory criteria for new drugs. We attempted to assess the entire information behind the

regulatory profession, including IND, NDA, clinical research investigations, and their methods. Finally, this paper concluded that the regulatory affairs department may interpret new drug products and processes, as well as monitor adherence to legal requirements.

ACKNOWLEDGEMENT

The corresponding author desires to explicit utmost gratitude to the Management and Prof. Dr. D. Ranganayakulu, M. Pharm., Ph. D., Principal, Sri Padmavati school of pharmacy, Tiruchanoor, Andhra Pradesh, India, for presenting all the necessary laboratory demands of the reviewand constant support.

Funding Support: The Author declares that there is no funding.

Conflict of Interest: The Author declares that there is no conflict of interest.

REFERENCES

[1] Monappa R. Sutar, Deepali R. Gawhane, and C.R.Tenpe. Study of Drug Regulatory Approval Process and Comparative Requirement of Common Technical Documents (CTD) in Europe, USA and India in Coordination with Drug Developmental Process. International Journal of Pharmaceutical Sciences Review and Research, 20(2):68-79, 2013.

[2] E.Gopinath, R.S. Bhadauria, Jodan Gunjan,and zaidi Insha. Pharmaceutical regulatory affairs – review. IJARPB, 2(2):292-301, 2012.

[3] D.K. Sanghi, and Rakesh Tiwle. Role of regulatory affairs in a pharmaceutical industry. IJPRR, 4(2): 127-131, 2014.

[4] Subash Philip, and Ansa Philip. The Scope of Regulatory Affairs in the Pharmaceutical Industry. Hygeia Journal for Drugs and Medicine, 2(1):1-6, 2010.

[5] G. Sushma, Subal debnath, Santhosh Kumar C, and Atul N Chandu. Quality and regulatory affairs of herbal drugs: A world-wide Review. Indo American Journal of Pharmaceutical Research, 1(5):389-396, 2011.

[6] Naishi Kirtikumar, and Dilip Maheshwari. Documentation Requirements for Generic Drug Application to be marketed in India-A Review. JPSBR, 4(4):237-242, 2014.

[7] Sumit Kumar, Rishabh Panwar, and Upendra Singh. Regulatory affairs in the pharmacy curriculum. International Journal of Research and Development in Pharmacy and Life Sciences, 2:690-698, 2013.

[8] Darrow JJ, Avorn J, and Kesselheim AS. Speed, safety, and industry funding—from PDUFA I to PDUFA VI. New England Journal of Medicine, 377(23):2278-2286, 2017.

[9] Atuah KN, Hughes D, and Pirmohamed M. Clinical pharmacology: Special safety considerations in drug development and pharmacovigilance. Drug Safety and International Journal of Medicine and Toxicology Drug Experience, 27: 535–54, 2004.

[10] Abodor H. Ethical issues in outsourcing: the case of contract medical research and the global pharmaceutical industry. Journal of Business Ethics, 105:239–55, 2012.

[11] Sushma Drabu, Alka Gupta, and Anupama Bhadauria. Emerging trends in contract research industry in India. Contemporary Clinical Trials, 31(5):419–22, 2010.

[12] Kennedy T. Strategic project management at the project level. Clinical Research and Regulation, 18:345–65, 2001.

[13] Anu Gummerus, Marja Airaksinen, Mia Bengtstrom, and Anne Juppo. Outsourcing of Regulatory Affairs Tasks in Pharmaceutical Companies—Why and What?. Journal of Pharmaceutical Innovation, 11:46–52, 2016.

[14] Yogendra K Gupta, and Biswa M Padhy. India's growing participation in global clinical trials. Trends in Pharmacological Sciences, 32(6):327-329., 2011.

[15] M. Lowman, P. Trott, A. Hoecht, and Z. Sellam. Innovation risks of outsourcing in pharmaceutical new product development. Technovation, 32(2):99–109, 2012.

[16] Nermeen Varawalla. India's growing clinical research sector: opportunity for global companies. IDrugs, 10(6):391-394, 2007.

[17] Henk Pander Maat, and Leo Lentz. Improving the usability of patient information leaflets. Patient Education and Counselling, 80(1):113–119, 2010.

[18] Ray Marks. Ethics and patient education: health literacy and cultural dilemmas. Health Promotion Practice, 10(3):328-32.
[19] Loren Miller. Commentary: outsourcing of regulatory activities: how a policy can drive good decisions. Therapeutic Innovation and Regulatory Science, 34(3):987-989, 2000.
[20] Giuseppe Borgheini. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clinical Therapeutics, 25(6):1578–1592, 2003.